Newsletter sign up



Copyright 2017
Terms & Conditions


Timothy Perren MD, FRCP, on Gynecological Cancer at the European Cancer Congress 2013

  • The ICON 7 trial: OS results of bevacizumab in women with newly diagnosed ovarian cancer
  • The ICON 6 trial: Data of anti-VEGF drug cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer
  • The Aurelia trial: results on chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer

This interview is produced in collaboration with



 

Copyright © 2012 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.